§5.02 Open Science.
(a) CARB-X supports the unrestricted access to the published research resulting from the Project and the public dissemination of the results or datasets underpinning any clinical trial or other preclinical or animal-based research, including positive and negative results.
(b) Therefore, the Subrecipient will endeavor to the greatest extent possible, consistent with timely filing of patent applications, to publish results from the Project (whether positive or negative and as described in (a) above), so that the results of this Project are placed in the peer-reviewed literature as soon as practical.
(c) The Subrecipient will make available any publications of research funded by CARB-X through PubMed Central (PMC) and Europe PubMed Central as soon as possible and in any event no later than six months from the date of final publication (in accordance with the access-policy”>Wellcome Trust’s Open Access Policy, and the ASPR Public Access Plan.
(d) The Subrecipient will provide the PTE with advance copies of all manuscripts related to the Project when they are submitted or re-submitted for publication. The PTE will have no role in the preparation, editing or approval of the manuscript. An unpublished patent application will not be deemed to be a manuscript for the purposes of this subsection (d).